1800 244 735

Helpline (02) 9874 9777

Successful gene therapy trial in Parkinson’s Disease gives hope for HD

Scientists have successfully used viruses to deliver genes to the brains of Parkinson’s Disease patients. The gene carried by the viruses improved the movement symptoms of patients receiving injections. This proves that gene therapy in the brain can work, providing hope for similar therapies in HD.

The connections between Parkinson’s and Huntington’s Disease

Like Huntington’s disease, Parkinson’s is a neurodegenerative condition. That means it is caused by the early death of brain cells called neurons. In some ways, the symptoms of HD and Parkinson’s might seem different – the characteristic feature of Parkinson’s disease patients is difficulty initiating movements, while the most obvious feature of HD is having too many movements. But brain circuits in the same neighborhood are involved in both diseases.

Deep beneath the convoluted outer layer of the brain (the ‘cortex’) are a set of structures called the ‘basal ganglia’. These parts of the brain are important for the regulation of movement, among other things. Different parts of the basal ganglia have opposing effects – some cause increased movement when cells in them fire, and others cause decreased movement. The part of the basal ganglia that is usually affected earliest in HD has the effect of inhibiting movement – so when it doesn’t function correctly, patients experience excess movements.

Gene Therapy versus ‘Small Molecules’

Most drugs are what scientists call ‘small molecules’. Those are simple chemicals designed to diffuse directly throughout the body and cause beneficial effects by binding to small machines in the cell called proteins. Most ‘small molecule’ drugs work by meeting the protein, and stopping the function of the protein.

It’s much easier to design drugs that stop proteins from working than to create drugs that make proteins do new things. Imagine a complex machine with spinning gears and intertwined parts. It’s easier to throw a rock into the gears and stop the machine then to add a new feature to it. So, the idea behind a lot of drug discovery is to find chemicals that stick to proteins and stop them from working.

But sometimes we know from animal models of disease that we need to make more of something happen, not less. In the case of Parkinson’s disease, it’s been shown in mice that more of a brain chemical called ‘GABA’ in part of the basal ganglia helps with symptoms. This animal finding was backed up in humans undergoing surgery for Parkinson’s – surgeons applied GABA directly to part of the basal ganglia and found that it temporarily improved the Parkinson’s symptoms.

Directly injecting GABA into the brain won’t work long-term, because the chemical is quickly used and degraded by the brain. So can we get this region of the brain to make more of its own GABA? A group of scientists and physicians decided to try to deliver a gene that instructs cells to make more GABA. If they could get this gene into this specific part of the basal ganglia, the brain would make its own GABA and that might be able to improve symptoms, as was seen temporarily when GABA was directly infused.

Delivering Gene Therapy

If it’s that easy, why not just inject the gene to tell cells to make more GABA? Unfortunately it’s not that simple. ‘Genes’ are actually made of long pieces of DNA. These are usually thousands of ‘letters’ connected in a long chain. In the case of the gene that tells brain cells to make more GABA, there’s over 3,000 ‘letters’ worth of DNA that need to get read. Getting that huge piece of DNA into cells is very tricky. If we were to simply inject DNA into the brain, very little of it would get into cells – most of it would just sit there doing nothing.

Step forward, viruses. These tiny germs are geniuses at transporting DNA from cell to cell, as anyone who’s ever had a cold knows. A virus is basically a protein package with a DNA cargo and specialist equipment for injecting that DNA into cells.

Scientists can modify viruses so that they can’t make more copies of themselves, but are still very handy at breaking into cells and delivering a cargo of genes. By loading up these harmless viruses with the genes they’re interested in, scientists can use them to deliver any gene to regions where it’s needed. In this case, the scientists used a virus called ‘adeno-associated virus (type 2)’, filled with copies of a gene that instructs cells to make more GABA.

The neurosurgeons involved with the study then injected this ‘genetically engineered’ virus into the basal ganglia of patients with advanced Parkinson’s Disease. As a ‘control’, some patients received injections that contained no viruses. Neither the doctors or patients knew whether they had received virus.

Did it work?

After 1, 3 and 6 months all the patients in the study were assessed by a specialist Parkinson’s doctor. Patients who had received the GABA gene virus did better than those patients who received control injections – showing nearly twice the improvement in motor function. The patients will now be followed for an additional 6 months to see whether these improvements persist.

How is this relevant to HD?

Many people believe that a technique called ‘huntingtin silencing’, is the best hope to change the course of HD. One approach to this technique is called ‘RNA interference’, or ‘RNAi’. The current thinking about using RNAi in the brain is that it will require direct injection into the brain, possibly using viruses.

This Parkinson’s Disease gene therapy study targeted a brain region very close to the likely target for future Huntington’s disease gene therapy trials. The fact that the surgeons were able to target this brain region successfully, and the viruses did their job of delivering a gene, proves that gene therapy can work in the brain. That provides hope that these techniques will be useful in similarly designed Huntington’s disease trials.

Latest Research Articles

Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps

Published date: 8 September, 2022

A group of scientists from the EPFL in Lausanne, Switzerland have published a paper in the Journal of the American Chemical Society, describing clumps made up of a fragment of the huntingtin protein. A word that’s commonly used to describe these is “aggregates.” Using very powerful microscopes, the team was able to zoom in and ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 4

Published date: 2 September, 2022

DNA repair and CAG repeat instability The effect of HTT lowering on CAG repeat expansions Welcome to last day of the @hdfcures conference! We’ll only be sharing a few talks from today’s sessions, which focus on DNA repair. The first is from HDBuzz’s very own Jeff Carroll! Jeff will be sharing his work on HTT ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 3

Published date: 1 September, 2022

Pre-clinical work moving toward trials New tools to lower HTT showing promise in animal models Welcome back! The first talk we will be tweeting about today is from Anastasia Khvorova, who will be telling us about her teams work on lowering of Huntingtin using technology called RNAi. One of the problems in studying drug delivery ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 2

Published date: 31 August, 2022

We’re back for day 2 at @hdfcures! This morning’s talks will be focused on clinical trial planning and therapeutic updates from clinical studies. The sheer number of talks related to human trials compared to previous years is so encouraging! Updating metrics for clinical trials A better system for disease categorization The first talk of this ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 1

Published date: 31 August, 2022

Hello and welcome from the HDBuzz team who are currently at the Hereditary Disease Foundation (@hdfcures) 2022 Milton Wexler Biennial Symposium in Boston! It’s the dawn of an exciting new era for HDBuzz. Due to our new partnership with @hdfcures, we are now able to live tweet many of the talks from this meeting which ... Read more

Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials

Published date: 29 August, 2022

Last month, we relayed positive news from uniQure’s trial testing AMT-130, a gene therapy delivered via brain surgery to lower huntingtin (HTT). Data released by uniQure in June suggested AMT-130 was safe and well tolerated in the small group of people that were treated with a low dose of the drug. Now we’re back to ... Read more